Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
NA-Selank Amidate Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
NA-Selank Amidate at a glance
What it is
A metabolically stabilized (N-terminal acetylated, C-terminal amidated) analog of Selank, a synthetic tuftsin-derived heptapeptide
Researched for
Reported in research and community contexts for anxiety, stress resilience, and cognitive/mood support
Commonly reported range
~250-900 mcg per day (some intranasal protocols report up to ~2700 mcg/day), in divided doses
Route reported
Intranasal spray/drops most common; subcutaneous injection also reported
Reported frequency
Two to three divided applications daily
Reported cycle
Community-reported cycles often run ~14-21 days
Plasma half-life
Parent Selank ~20-30 min; the acetylated/amidated analog is reported to be longer-acting (community estimates vary widely)
Regulatory status
Not FDA-approved; parent Selank approved in Russia/Ukraine for anxiety disorders; sold elsewhere as research-use-only. Not currently listed on the WADA Prohibited List
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Selank is a synthetic analog of the immunomodulatory peptide tuftsin, and N-Acetyl Selank Amidate is a modified version carrying an N-terminal acetyl group and a C-terminal amide intended to slow enzymatic breakdown by aminopeptidases and carboxypeptidases. In preclinical research, Selank is reported to modulate GABAergic signaling in a manner that produces anxiolytic effects without engaging the benzodiazepine binding site, which researchers associate with a lower dependence profile. Studies also describe effects on serotonergic and monoaminergic neurotransmission, as well as reported changes in expression of brain-derived neurotrophic factor (BDNF). Additional research points to inhibition of enkephalin-degrading enzymes, which may prolong endogenous regulatory peptide activity. These are proposed mechanisms drawn largely from animal and early human studies of Selank, not confirmed mechanisms for the acetylated/amidated analog specifically.
Researched effects
In the research literature and community reports, Selank and its analogs are described in connection with reduced anxiety-like behavior, improved stress resilience, and support for attention and mood, generally without the sedation associated with classic anxiolytics. Some reports also describe effects on sleep quality and immune-related signaling. These are research findings and community-reported observations, not guaranteed outcomes, and human data on N-Acetyl Selank Amidate specifically remains very limited.
Evidence & regulatory status
Evidence base: Most controlled data comes from Russian preclinical and small clinical studies of the parent peptide Selank; direct human trials on the N-acetyl amidate analog are lacking, so effects are inferred from Selank plus mechanistic reasoning.
Regulatory: Parent Selank is approved in Russia and Ukraine for generalized anxiety disorder and neurasthenia; it is not FDA-approved in the United States, and the analog is not approved for human use anywhere.
Research-use: In the US and most markets this compound is sold strictly for laboratory and research use only and is not intended for human consumption.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in research protocols and community sources, not a recommendation or a personal dose. Reported intranasal use of Selank and its analogs commonly falls in the ~250-900 mcg per day range, split into two or three applications, with some study protocols going higher (up to roughly 2700 mcg/day in divided doses over short courses). Community-reported cycles frequently run about 14-21 days. Because human data on the acetylated/amidated analog is sparse, reported ranges vary widely between sources.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Reconstitution is concentration math only, not a personal dose. Because this peptide is dosed in micrograms (mcg), it helps to work in mcg/mL. When you add W mL of bacteriostatic water to a vial containing V mg of peptide, the concentration is (V x 1000) / W mcg/mL. To find syringe units on a U-100 insulin syringe, use: units = (desired mcg / concentration in mcg/mL) x 100. Worked example: a representative 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 10,000 mcg / 2 mL = 5,000 mcg/mL. A 250 mcg example draw would be 250 / 5,000 = 0.05 mL, which is 5 units on a U-100 syringe. The same volume math applies if measuring intranasal spray fills.
Bac water added
Concentration
250 mcg (low example)
750 mcg (high example)
1 mL
10,000 mcg/mL (10 mg/mL)
2.5 units
7.5 units
2 mL
5,000 mcg/mL (5 mg/mL)
5 units
15 units
3 mL
3,333 mcg/mL (~3.33 mg/mL)
7.5 units
22.5 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
6 units
= 0.06 mL · 300 mcg target amount
Concentration
5mg/mL
Per insulin unit
50mcg
Portions per vial
33.3
Volume
0.06mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In research settings, Selank-class peptides are most often reported as an intranasal spray or drops, with subcutaneous administration also described. For subcutaneous handling, reports describe reconstituting with bacteriostatic water, drawing the calculated volume on a U-100 insulin syringe, and rotating sites (abdomen is commonly mentioned). Intranasal use is typically measured by spray-pump volume rather than syringe units. All of this is background on how the compound is handled in research, not instructions for human use.
Half-life & frequency rationale
The parent peptide Selank has a reported plasma half-life on the order of 20-30 minutes, reflecting rapid peptidase degradation. N-Acetyl Selank Amidate is designed with terminal modifications intended to resist that degradation, and community and vendor sources describe it as longer-acting, though published pharmacokinetic values for the analog are scarce and reported estimates vary widely. Intranasal bioavailability for Selank is often cited in the 60-80% range in secondary sources.
Side effects, safety & contraindications
Reported side effects are generally mild and, for intranasal use, include nasal dryness, throat irritation, and hypersensitivity reactions; injection-related reports include site pain, redness, or swelling. Selank is generally described as well tolerated in the available Russian studies, but human safety data specifically for the N-acetyl amidate analog is limited, and long-term safety is not established. This is a summary of reported observations, not a safety guarantee.
Stacking — overview
The most widely discussed pairing is Selank with Semax, another Russian heptapeptide, combining Selank's reported anxiolytic/GABAergic profile with Semax's reported cognitive and BDNF-related effects for a "calm focus" concept. Note that this pairing is based on mechanistic reasoning and community experience rather than controlled human trials. Other community-reported combinations draw on peptides in the same nootropic and recovery categories. These are examples of what is reported, not recommendations.
Calm-Focus Nootropic Pairing
N-Acetyl Selank Amidate + Semax
Mood and Sleep Support
N-Acetyl Selank Amidate + DSIP
Stress and Recovery
N-Acetyl Selank Amidate + Epithalon
Storage & handling
Lyophilized (powder): store refrigerated at about 2-8 C (36-46 F); protect from light and moisture. Many sources note the powder is stable frozen for longer-term storage.
Reconstituted (in bacteriostatic water): keep refrigerated at 2-8 C and use within a few weeks; avoid freeze-thaw cycles and keep away from heat and light.
References
This guide summarizes secondary research and community sources on Selank and N-Acetyl Selank Amidate (including peptides.org, wholisticresearch.com, and Russian preclinical/clinical literature on Selank) and is provided for educational purposes only, not as medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is the difference between N-Acetyl Selank Amidate and regular Selank?
N-Acetyl Selank Amidate is the same core Selank sequence with an added N-terminal acetyl group and C-terminal amide. These modifications are intended to slow enzymatic breakdown, and sources describe the analog as longer-acting than standard Selank, though robust pharmacokinetic data on the analog is limited.
Is N-Acetyl Selank Amidate FDA-approved?
No. It is not FDA-approved. The parent peptide Selank is approved in Russia and Ukraine for anxiety-related indications, but the analog is not approved for human use anywhere and is sold in most markets strictly for research use only.
Is it banned in sports?
As of this writing, Selank and its analogs are not specifically named on the WADA Prohibited List. Athletes should always verify current WADA rules directly, since substances can be added or reinterpreted and this is not compliance advice.
How is it typically administered in research?
Intranasal spray or drops is the most commonly reported route, with subcutaneous injection also described. Reported protocols use divided daily doses; the numbers in this guide are examples reported in sources, not a recommendation.
How should it be stored?
Lyophilized powder is typically kept refrigerated (about 2-8 C) or frozen for longer storage, while reconstituted solution is kept refrigerated and used within a few weeks, avoiding freeze-thaw cycles.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
